Publications by authors named "Jane Stock"
Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease.
View Article and Find Full Text PDFArticle Synopsis
- In 2022, the European Atherosclerosis Society released a consensus statement highlighting the link between lipoprotein(a) [Lp(a)] levels and an increased risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
- A new risk calculator was introduced to help assess an individual's lifetime risk for ASCVD, particularly noting that those with high Lp(a) levels may be at greater risk than previously understood.
- The statement also offers practical guidance for managing cardiovascular risk based on Lp(a) levels and addresses common questions regarding Lp(a) measurement and treatment options in everyday clinical practice.
This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation.
View Article and Find Full Text PDFArticle Synopsis
- * It recommends testing Lp(a) levels in adults, especially those with a family history of high Lp(a) or premature ASCVD, and suggests aggressive management of cardiovascular risk factors in the absence of specific Lp(a)-lowering therapies.
- * The statement underscores the need for further research into Lp(a)-lowering treatments while recognizing Lp(a) as a causal risk factor for cardiovascular conditions, reinforcing
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD).
View Article and Find Full Text PDFBackground And Aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.
Methods: Evidence-based review.
Results: Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients.